Lantern Pharma Statistics
Want to see LTRN full AI Analyst Report?
Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics
Total Valuation
Lantern Pharma has a market cap or net worth of $6.92M. The enterprise value is $44.48M.
- Market Cap
- $6.92M
- Enterprise Value
- $44.48M
Share Statistics
Lantern Pharma has 14,935,576 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 14,935,576
- Owned by Insiders
- 0.96%
- Owned by Institutions
- 6.54%
Financial Efficiency
Lantern Pharma’s return on equity (ROE) is -2.62 and return on invested capital (ROIC) is -21.13%.
- Return on Equity (ROE)
- -2.62
- Return on Assets (ROA)
- -1.55
- Return on Invested Capital (ROIC)
- -21.13%
- Return on Capital Employed (ROCE)
- -2.75
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.07M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lantern Pharma is -0.29. Lantern Pharma’s PEG ratio is -0.04.
- PE Ratio
- -0.29
- PS Ratio
- 0.00
- PB Ratio
- -1.79
- Price to FCF
- -0.49
- Price to Operating Cash Flow
- -0.41
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Lantern Pharma had revenue of 0 and earned -17.12M in profits. Earnings per share was -1.57.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -17.98M
- Pretax Income
- -17.12M
- Net Income
- -17.12M
- EBITDA
- -17.10M
- Earnings Per Share (EPS)
- -1.57
Cash Flow
In the last 12 months, operating cash flow was -14.08M and capital expenditures -564, giving a free cash flow of -14.08M billion.
- Operating Cash Flow
- -14.08M
- Free Cash Flow
- -14.08M
- Free Cash Flow per Share
- -1.13
Dividends & Yields
Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -200.51%
- Earnings Yield
- -319.39%
Stock Price Statistics
- Beta
- 2.38
- 52-Week Price Change
- -86.96%
- 50-Day Moving Average
- 1.13
- 200-Day Moving Average
- 2.37
- Relative Strength Index (RSI)
- 26.83
- Average Volume (3m)
- 246.00K
Important Dates
Lantern Pharma upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Lantern Pharma as a current ratio of 2.40, with Debt / Equity ratio of 1201.96%
- Current Ratio
- 2.40
- Quick Ratio
- 2.40
- Debt to Market Cap
- 2.38
- Net Debt to EBITDA
- -4.33
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lantern Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lantern Pharma EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.03.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.03
- EV to Operating Cash Flow
- -0.03
Balance Sheet
Lantern Pharma has $7.36M in cash and marketable securities with $39.72K in debt, giving a net cash position of $7.32M billion.
- Cash & Marketable Securities
- $7.36M
- Total Debt
- $39.72K
- Net Cash
- $7.32M
- Net Cash Per Share
- $0.49
- Tangible Book Value Per Share
- -$0.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Lantern Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 9.68%
Scores
- Smart Score
- ―
- AI Score
- 44
